Biotech is Set to Acquire Instadeep.
InstaDeep Ltd., a top global technology company in the fields of artificial intelligence (“AI”) and machine learning, and BioNTech Inc. announced that they have entered into an agreement under which BioNTech will acquire InstaDeep (“ML”).
About 240 highly skilled workers, including teams in AI, ML, bioengineering, data science, and software development, are anticipated to join BioNTech’s workforce as a result of the merger of two organizations with similar cultures.
Individualized and commercially available mRNA-based therapies, cutting-edge chimeric antigen receptor T cells, bispecific immune checkpoint modulators, specifically targeted cancer antibodies, and small molecules are all part of its diverse portfolio of oncology product candidates.
BioNTech and its partners are developing a number of mRNA vaccine candidates for a variety of infectious diseases based on their extensive experience in the development of mRNA vaccines and internal manufacturing capabilities.
Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.